Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Stefanie Aust, Anna Bachmayr-Heyda, Petra Pateisky, Dan Cacsire Castillo-Tong, Silvia Darb-Esfahani, Carsten Denkert, Radoslav Chekerov, Jalid Sehouli, Sven Mahner, Toon Van Gorp, Ignace Vergote, Paul Speiser, Reinhard Horvat, Robert Zeillinger, Dietmar Pils*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor ? (ER?) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ER? expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ER? in regard to clinicopathological parameters, chemotherapy response, and survival.Expressions of TRAP1 and ER? were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ER? was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ER? (p
Original languageEnglish
Pages (from-to)69
JournalMolecular Cancer
Publication statusPublished - 14 Sept 2012


  • TRAP1
  • Estrogen receptor
  • Immunohistochemistry
  • Prognosis
  • Ovarian cancer

Cite this